Acyclovir Sodium 274 4Mg Eqv Acyclovir

證據等級: L5

預測適應症: 0 個

Acyclovir Sodium: No Repurposing Predictions Available

One-Sentence Summary

Acyclovir sodium is a nucleoside analogue antiviral classically used to treat herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. The current Evidence Pack contains no TxGNN repurposing predictions, returned zero Singapore regulatory registrations, and is missing mechanism of action and safety data — a full repurposing evaluation cannot be completed at this stage. The data pipeline appears to have encountered critical gaps that must be resolved before proceeding.

Quick Overview

Item	Content
Original Indication	Herpes simplex and varicella-zoster infections (based on pharmacological knowledge; no local regulatory data retrieved)
Predicted New Indication	None — TxGNN predictions not generated
TxGNN Prediction Score	N/A
Evidence Level	Cannot be determined
Singapore Market Status	Not marketed (0 registrations found)
Number of Registrations	0
Recommended Decision	Hold

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This Evidence Pack is critically incomplete — no repurposing predictions were generated by TxGNN, Singapore regulatory data returned zero results, and both mechanism of action and safety data are absent. Without a candidate indication from the model, there is nothing to evaluate.

To proceed, the following is needed:

Fix the drug identifier: The query used the full formulation string "ACYCLOVIR SODIUM 274.4MG EQV. ACYCLOVIR" (which embeds a dosage). This non-standard name likely caused all downstream lookups to fail. Resubmit using the INN acyclovir or DrugBank ID DB00787.
Re-run the TxGNN pipeline with the corrected identifier to generate repurposing candidate predictions.
Investigate the Singapore HSA lookup: Acyclovir is a decades-old antiviral widely registered globally (including in Singapore as Zovirax and generics). A result of 0 registrations strongly suggests a pipeline error, not a true market absence.
Extract DrugBank data: The query log shows a successful DrugBank API response (1 result found), but the data was not written to the Evidence Pack. The MOA and safety information are available — they simply need to be parsed and populated.
Obtain HSA package insert for Singapore-specific warnings, contraindications, and approved indications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.